Efficacy and safety of Shulie'an capsules in treating chronic prostatitis: A multicenter, prospective, open-label clinical trial
Abstract
Background and Objectives: Chronic prostatitis is a highly prevalent urological disorder affecting millions of men globally and significantly impairing quality of life. The aim of this study was to evaluate the efficacy and safety of Shulie'an (SLA) capsules in patients with chronic prostatitis. Methods: In this multicenter, prospective, open-label, self-controlled clinical trial, 100 male patients with clinically confirmed chronic prostatitis were enrolled in China. The participants received oral SLA (two capsules per dose, three times daily) for 28 days. The primary endpoint was the change in the National Institutes of Health Chronic Prostatitis Symptom Index (NIH-CPSI) total score from baseline to endpoint. Secondary endpoints included NIH-CPSI individual domain scores and disappearance rate of traditional Chinese medicine (TCM) symptoms. Safety assessments involved monitoring and recording all adverse events throughout the study period. Results: After 28 days of treatment, SLA capsules exhibited significant clinical efficacy, with an overall response rate of 91.75%. The mean NIH-CPSI total score reduction was 9.2±5.82 and 15.0±6.79 points on the 14th and 28th day, respectively. Approximately 95.88% of the participants achieved more than 4-point reduction in the NIH-CPSI score from baseline after treating for 28 days. All symptom domains showed statistically significant improvements, with symptoms of pain being the most remarkable (complete resolution rate: 41.57%).…
Read the paper
Related studies
- Pathophysiology of Overactive Bladder and Pharmacologic Treatments Including β3-Adrenoceptor Agonists -Basic Research Perspectives-
- Exosomal Liquid Biopsy in Prostate Cancer: A Systematic Review of Biomarkers for Diagnosis, Prognosis, and Treatment Response
- Leveraging glycosylation for early detection and therapeutic target discovery in pancreatic cancer
- Rethinking of phosphodiesterase 5 inhibition: the old, the new and the perspective in human health
- Long-term outcomes after treatment with Optilume BPH: Four-year results from the EVEREST study
- Future aspects of plant derived bioactive metabolites as therapeutics to combat benign prostatic hyperplasia
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.